National Cancer Institute (NCI)s

National Cancer Institute (NCI)

428 Protocols (241 Active Accrual of new subjects, 187 Follow-up of previously enrolled subjects)


Active Accrual, Protocols Recruiting New Patients 
* 19-C-0040:
Natural History Study of Men at High Genetic Risk for Prostate Cancer

* 19-C-0017:
Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

* 19-C-0016:
Natural History and Biospecimen Acquisition Study for Children and Adults with Rare Solid Tumors

* 19-C-0002:
A Phase II Study of M7824 in Subjects with Recurrent Respiratory Papillomatosis

* 18-C-0147:
Phase 1 with Expansion Cohorts in a Study of NEO-201 In Adults with Chemo-Resistant Solid Tumors

* 18-C-0143:
A Phase 1 Study of Intraperitoneal MCY-M11 Therapy for Women with Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects with Peritoneal Mesothelioma with Recurrence after Prior Chemotherapy

* 18-C-0141:
Phase II Study Evaluating Confocal Endoscopic Microscopy for Detection of Early Stage Gastric Cancer in Subjects with Hereditary Diffuse Gastric Cancer Syndrome

* 18-C-0138:
An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma

* 18-C-0137:
Phase II Clinical Trial of Sunitinib in Sarcomas of the Central Nervous System

* 18-C-0136:
Phase II Study of the Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma

* 18-C-0135:
Phase II Trial of Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation

* 18-C-0130:
PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma

* 18-C-0126:
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)

* 18-C-0125:
A Phase I Clinical Trial of T cells Expressing a Novel Fully-human Anti-BCMA CAR for Treating Multiple Myeloma

* 18-C-0122:
Phase IB Combination Study of Copanlisib and Nivolumab in Advanced Solid Tumors and Lymphomas

* 18-C-0119:
An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1 with Inoperable, Progressive/Symptomatic Plexiform Neurofibromas

* 18-C-0110:
Safety Run-In and Phase II Trial of M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

* 18-C-0097:
Phase II Study of Olaparib in Subjects with Malignant Mesothelioma

* 18-C-0096:
A Single Arm Phase II Study Combining CRLX101, a Nanoparticle Camptothecin, with Enzalutamide in Patients with Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment

* 18-C-0093:
Pilot Study of Medication Adherence in Children, Adolescents, and Adults with Neurofibromatosis Type 1 (NF1) on Clinical Treatment Trials

* 18-C-0088:
Use of CV301 for the Treatment of Triple Positive Metastatic Breast Cancer

* 18-C-0080:
Feasibility and Preliminary Efficacy of a Mindfulness-based Intervention for Children with High Grade Brain Tumors and Their Caregivers

* 18-C-0078:
Phase I/II Study of Immunotherapy Combination BN-Brachyury vaccine, M7824, ALT-803 and Epacadostat (QuEST1)

* 18-C-0076:
Bicalutamide With or Without Metformin for Biochemical Recurrence in Prostate Cancer Patients (BIMET-1)

* 18-C-0074:
A Phase I/II Trial to Evaluate the Safety and Immunogenicity of a messenger RNA (mRNA)-based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer

* 18-C-0073:
Treatment of Patients with Castration Resistant Prostate Cancer using a Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccine

* 18-C-0070:
Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer

* 18-C-0059:
Phase 1 Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults with Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

* 18-C-0058:
A Pilot Study to Evaluate the Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration in Men with Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females

* 18-C-0056:
M7824 in Subjects with HPV Associated Malignancies

* 18-C-0049:
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive against Mutated Neoantigens in People with Metastatic Cancer

* 18-C-0043:
Generation of Cancer Antigen-Specific T-cells from Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential Future Therapy

* 18-C-0038:
Long Term Follow-up of Subjects Exposed to NY-ESO-1c259T, a Genetically Engineered NY-ESO-1 Specific T Cell Receptor

* 18-C-0034:
A Phase 2 Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

* 18-C-0033:
Phase I Study of Recombinant Interleukin-15 in Combination with Checkpoint Inhibitors Nivolumab and Ipilimumab in People with Refractory Cancers

* 18-C-0028:
Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy

* 18-C-0026:
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (BALL)

* 18-C-0017:
Profiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer

* 18-C-0014:
Phase I Trial of 5-aza-4'-thio-2'-Deoxycytidine (Aza-TdC) in Patients with Advanced Solid Tumors

* 18-C-0008:
Phase III randomized Adjuvant study of MK-3475 (pembrolizumab) in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) versus Observation

* 18-C-0005:
Phase II Trial of Combination Immunotherapy in Biochemically Recurrent Prostate Cancer

* 17-C-0177:
A Phase II Trial to Evaluate the Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer

* 17-C-0175:
CC-4047-BRN-001: A Phase 2 Clinical Study of Pomalidomide (CC-4047) Monotherapy for Children and Young Adults with Recurrent or Progressive Primary Brain Tumors

* 17-C-0174:
Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease

* 17-C-0164:
A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

* 17-C-0157:
A Phase I Single-Arm Study of the Combination of Durvalumab (MEDI4736) and Vicinium (Oportuzumab Monatox, VB4-845) in Subjects with High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated with BCG

* 17-C-0156:
Longitudinal Sample Collection and Tracking for the Developmental Therapeutics Clinic, National Cancer Institute

* 17-C-0153:
Phase I Trial of Image Guided Focally Dose Escalated Prostate SBRT for Locally Recurrent Prostate Cancer after Prior Radiotherapy

* 17-C-0149:
Phase 2 Trial of Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma(PCNSL), and other Extranodal Diffuse Large B-cell Lymphomas

* 17-C-0144:
A Phase II Study of Selumetinib (AZD6244) for the Treatment of Advanced Pancreas Cancer Harboring KRAS G12R Mutations

* 17-C-0140:
Phase I/II Evaluation of the Immune Checkpoint Inhibitor, Pembrolizumab in Combination with Oral Decitabine and Tetrahydrouridine as First-Line Therapy for Inoperable, or Unresectable Locally Advanced or Metastatic Non-small Cell Lung Cancer

* 17-C-0137:
Leukapheresis for CAR-Therapy Manufacturing

* 17-C-0127:
Phase 1b Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

* 17-C-0125:
Phase 2 Trial of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

* 17-C-0117:
A Phase 1/2a, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of PEN-866 in Advanced Solid Malignancies

* 17-C-0116:
A Phase I Study of Immunotherapy with E6 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions

* 17-C-0115:
Phase I/II Study of T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery

* 17-C-0113:
Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A 1101 Patients

* 17-C-0109:
(18)F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer

* 17-C-0105:
Prospective Study of Clonal Evolution in Follicular Lymphoma

* 17-C-0102:
Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients with Select Rare CNS Cancers

* 17-C-0100:
Collection of Malignant Ascites, Pleural Fluid, and Blood from Patients with Solid Tumors

* 17-C-0092:
A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination with Immune Checkpoint Inhibition in Refractory Colorectal Cancer

* 17-C-0090:
DART: Dual Anti-CTLA-4 And Anti-Pd-1 Blockade In Rare Tumors

* 17-C-0089:
Evaluation of 18F-DCFPyL PSMA- versus 18F-NaF-PET imaging for Detection of Metastatic Prostate Cancer

* 17-C-0088:
A Phase II Trial of the DNA Methyl Transferase Inhibitor, SGI-110 (Guadecitabine), In Children And Adults With Wild Type GIST, Pheochromocytoma And Paraganglioma Associated With Succinate Dehydrogenase Deficiency And HLRCC-Associated Kidney Cancer

* 17-C-0087:
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

* 17-C-0084:
A Phase II Trial of the Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Patients with Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)

* 17-C-0082:
A Phase 2 Study of Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination with Capecitabine and Oxaliplatin (CAPOX) in Subjects with Advanced Biliary Tract Carcinoma (BTC)

* 17-C-0074:
A Phase 2 Study of Anti-PD-L1 Antibody Atezolizumab in Alveolar Soft Part Sarcoma

* 17-C-0070:
Phase II Trial of Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer with Positive Peritoneal Cytology

* 17-C-0066:
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma after Progression on Platinum-Based Chemotherapy

* 17-C-0057:
A Randomized Phase II Trial of Standard of Care Alone or in Combination with Ad-CEA Vaccine and Avelumab in Patients with Previously Untreated Metastatic or Unresectable Colorectal Cancer

* 17-C-0049:
A Phase I/II Trial of the Insulin-Like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination with the Src Family Kinase (SFK) Inhibitor Dasatinib in Patients with Embryonal and Alveolar Rhabdomyosarcoma

* 17-C-0048:
T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas

* 17-C-0044:
Prospective Evaluation and Molecular Profiling in Patients with Gastric Tumors

* 17-C-0043:
Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer

* 17-C-0038:
A Phase Ib Open Label, Dose Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination with M9241 (NHS-IL12) in Subjects with Locally Advanced, Unresectable, or Metastatic Solid Tumors

* 17-C-0034:
A Randomized, Double Blind Phase II Trial of Surgery, Radiation Therapy Plus Temozolomide and Pembrolizumab with and without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)

* 17-C-0028:
A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo ) in Combination with UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults with Relapse of Acute Lymphoblastic Leukemia

* 17-C-0027:
Long-Term Follow up of Patients Undergoing Hematopoietic Stem Cell Transplantation

* 17-C-0023:
A Phase 1/2 Trial of CV301 In Combination with Anti-PD-1 Therapy Versus Anti-PD-1 Therapy Alone in Subjects with Non-Small Cell Lung Cancer

* 17-C-0012:
Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors

* 17-C-0011:
Phase 1 Study of Intraperitoneal Infusion of Autologous Monocytes with Sylatron (Peginterferon alfa-2b) and Actimmune (Interferon gamma-1b) in Women with Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

* 17-C-0009:
Phase I Trial of TG02 Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of TG02 plus Temozolomide versus Temozolomide alone in Adults with Recurrent Anaplastic Astrocytoma and Glioblastoma

* 17-C-0007:
Phase I/II Study of PROSTVAC in Combination with Nivolumab in Men with Prostate Cancer

* 16-C-0171:
Phase I/II Study of Lenalidomide Combined with Modified DA-EPOCH and Rituximab (EPOCH-R(2)) In Primary Effusion Lymphoma or KSHV-Associated Large Cell Lymphoma

* 16-C-0154:
A Phase I/II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 with or without PD-1 Blockade for HPV-Associated Cancers

* 16-C-0151:
Evaluation of the Natural History of and Specimen Banking for Patients with Tumors of the Central Nervous System

* 16-C-0138:
Collection of Peripheral Blood Mononuclear Cells (PBMCs) from Healthy Subjects for the Expansion of T Cells for Adoptive Cell Therapy

* 16-C-0135:
A Pilot Study of Combined Immune Checkpoint Inhibition in combination with Ablative Therapies in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

* 16-C-0131:
A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a CD70-Binding Chimeric Antigen Receptor to Patients with CD70 Expressing Cancers

* 16-C-0128:
A Phase Ib/II Study of Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination with Nab-Paclitaxel in Participants with Previously Treated Metastatic and/ or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors

* 16-C-0121:
A Pilot Clinical Trial of Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma

* 16-C-0109:
Phase 1 Trial of the Combination of the Heat Shock Protein-90 (HSP90) Inhibitor Onalespib (AT13387) and the Cyclin-Dependent Kinase (CDK) Inhibitor AT7519 in Patients with Advanced Solid Tumors

* 16-C-0107:
A Phase I/II Trial of CRLX101, a Nanoparticle Camptothecin with Olaparib in Patients with Relapsed/Refractory Small Cell Lung Cancer

* 16-C-0097:
Phase 1 Trial of Panobinostat in Children with Diffuse Intrinsic Pontine Glioma

* 16-C-0094:
A Phase 1/2 Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease (cGVHD) after Allogeneic Hematopoietic Stem Cell Transplantation (SCT)

* 16-C-0092:
A Pilot Study of Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-mutated, Non-Small Cell Lung Cancer (NSCLC) After Treatment with Osimertinib (AZD9291, Tagrisso)

* 16-C-0091:
Long-Term Follow-up of Subjects Treated with bb2121

Next 100 Protocols

02/16/2019